• Home
  • News
  • Fortune 500
    • Fortune Global 500
    • Fortune 500 Europe
    • Fortune China 500
    • Fortune SEA 500
    • Great Place to Work
  • Tech
    • AI
    • Innovation
    • Cybersecurity
  • Finance
    • Personal Finance
    • Real Estate
    • Economy
    • Investing
    • Banking
    • Crypto
  • Leadership
    • Success
    • Future of Work
    • Workplace Culture
    • C-Suite
    • CEO Initiative
  • Lifestyle
    • Arts & Entertainment
    • Travel & Leisure
    • Health
    • Well
    • Education
  • Rankings
    • Analytics
  • Multimedia
    • Live Media
    • Magazine
    • Newsletters
    • Video
    • Podcasts
  • Home
  • News
  • FORTUNE 500
    • FORTUNE 500
    • FORTUNE SEA 500
    • Fortune 500 Europe
    • Fortune Global 500
    • Fortune China 500
    • Great Place to Work
  • Tech
    • Tech
    • AI
    • Innovation
    • Cybersecurity
  • Finance
    • Finance
    • Personal Finance
    • Real Estate
    • Economy
    • Banking
    • Investing
    • Crypto
  • Leadership
    • Leadership
    • Success
    • Future of Work
    • Workplace Culture
    • C-Suite
    • CEO Initiative
  • Lifestyle
    • Lifestyle
    • Arts & Entertainment
    • Travel & Leisure
    • Health
    • Well
    • Education
  • Rankings
    • Rankings
    • Analytics
  • Multimedia
    • Multimedia
    • Live Media
    • Magazine
    • Newsletters
    • Video
    • Podcasts
  • Asia
  • Europe
  • Analytics
  1. home
  1. home
  2. Teva

Teva

Page 2 of 2

J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
Finance

Biotech Stocks Crashed and Nobody Knows Why

By Jen Wieczner
January 29, 2016
Pfizer employees inside of a laboratory at Pfizer's research and development facility in Cambridge, Massachusetts, U.S., on Monday, Oct. 26, 2015. Photographer: Scott Eisen/Bloomberg *** Local Caption ***
Finance

Why Pfizer Is Headed for Splitsville After Allergan Merger

By Jen Wieczner
November 19, 2015
14th Annual Elton John AIDS Foundation An Enduring Vision Benefit - Show
Finance

Why Mylan Just Lost The Largest Hostile Takeover Battle Ever

By Jen Wieczner
November 13, 2015
Mylan Buys Abbott Laboratories Generic Drug Business For $5.3 Billion
Health

Mylan’s Hostile Bid for Perrigo Fails

By Reuters
November 13, 2015
A Teva Pharmaceutical Industries factory in Jerusalem, Israel.
Finance

The real reasons for the pharma merger boom

By Jen Wieczner
July 28, 2015
Inside Teva Pharmaceuticals Headquarters
Commentary

Teva buys Allergan: 3 reasons why it’s a blockbuster deal

By S. Kumar
July 27, 2015

Most Popular

  • North America
    Farmer says 'we're in a very dire situation' ahead of harvest—with zero soybean orders from China, historically the...
    By Dave Smith
  • Success
    Workday’s CEO says his career took off after he changed his attitude—and Amazon boss Andy Jassy swears by the same...
    By Preston Fore
  • Success
    This Stanford computer science professor went to written exams 2 years ago because of AI. He says his students insisted...
    By Nick Lichtenberg
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • MPW
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms of Use
  • Single Issues for Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work at Fortune
  • Diversity and Inclusion
  • Terms and Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.